RNA Medicines Enter ‘Second Act’ Post-COVID-19, Focusing on Extrahepatic Delivery Beyond the Liver

July 26, 2026

European Biotechnology Magazine Germany

Overview

RNA therapeutics are entering a ‘second act’ after the success of mRNA vaccines during the COVID-19 pandemic, with a critical focus on developing effective delivery technologies to extrahepatic organs. While siRNA therapies from companies like Alnylam, Arrowhead, and Silence Therapeutics are clinically established, driven by liver-targeting GalNAc conjugate approaches, the future hinges on next-generation RNA technologies (e.g., microRNA, self-amplifying RNA, circular RNA) and advanced delivery systems capable of reaching tissues beyond the liver. Overcoming this delivery challenge is paramount for RNA medicines to fulfill their broad therapeutic potential in diverse diseases.

In Depth

Key Findings

RNA therapeutics are embarking on their ‘second act,’ building on the unprecedented success of mRNA vaccines during the COVID-19 pandemic. This new phase is characterized by a strategic pivot towards developing sophisticated delivery technologies that can effectively transport RNA molecules to extrahepatic organs such as the lungs, muscle, central nervous system, and solid tumors, moving beyond the liver-centric approaches that have dominated initial developments.

Technical and Clinical Details

Currently, small interfering RNA (siRNA) therapeutics are the most clinically established RNA modality, with companies like Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics leading the charge. The success of many siRNA drugs, particularly those targeting liver-related diseases, has been largely attributed to the effective use of N-acetylgalactosamine (GalNAc) conjugation. This technology enables highly specific and efficient delivery of siRNAs to hepatocytes, making the liver a readily accessible target.

However, to unlock the full therapeutic potential of RNA medicines for a wider array of diseases, delivery to non-hepatic tissues is crucial. To address this, significant research and development efforts are underway in next-generation RNA technologies. These include microRNAs, self-amplifying RNAs (saRNAs), and circular RNAs (circRNAs), which offer novel mechanisms for disease intervention. Concurrently, advanced delivery systems such as optimized lipid nanoparticles (LNPs), polymer-based conjugates, peptide conjugates, and exosome-based carriers are being explored to achieve targeted delivery to specific cells and tissues outside the liver, aiming to overcome the biological barriers that limit systemic RNA distribution.

Background and Context

The journey of RNA medicine has been a long one, marked by decades of fundamental research and punctuated by the transformative clinical impact of mRNA vaccines. The COVID-19 pandemic vividly demonstrated the speed and efficacy with which mRNA vaccines could be developed and deployed, fundamentally altering global perceptions of RNA technology. This success has ignited an explosion of scientific and investment interest, accelerating the quest for solutions to previously intractable delivery challenges.

Given the liver’s role as a central metabolic organ, early RNA therapeutics naturally gravitated towards hepatic targets. However, the pressing need to address a broader spectrum of human diseases mandates the development of reliable extrahepatic delivery strategies. Solving this challenge promises to dramatically expand the applicability of RNA medicines from rare genetic disorders to common conditions such as cancer, cardiovascular diseases, and neurodegenerative disorders.

Strategic Significance and Outlook

The outlook for RNA medicine in its ‘second act’ is exceptionally promising. Advances in extrahepatic delivery technologies are poised to break current limitations, leading to the creation of novel and highly effective therapeutics. Should successful delivery to challenging targets like the central nervous system or solid tumors be achieved, RNA medicines could cement their position as one of the most powerful tools in modern medicine. Investors are keenly interested in platforms demonstrating innovative technologies for delivering RNA at therapeutic doses to the right cells, ensuring continued robust research, development, and strategic partnerships in this rapidly evolving field.

Source: https://european-biotechnology.com/background/rna-medicine-enters-its-second-act/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.